Literature DB >> 11940214

Aberrant expression of pRb, p16, p14ARF, MDM2, p21 and p53 in stage I adenocarcinomas of the lung.

Qi Xue1, Takaaki Sano, Kenji Kashiwabara, Masako Saito, Tetsunari Oyama, Takashi Nakajima.   

Abstract

Cancers are always associated with cell cycle abnormalities. To clarify the cell cycle abnormalities present in lung adenocarcinomas, various cell cycle regulatory proteins of both the pRb and p53 pathways were studied immunohistochemically in 50 cases of stage I adenocarcinoma of the lung. In regard to the pRb pathway, most adenocarcinomas showed frequent expression of both p16 and pRb proteins, and aberrant expression in the pRb pathway was observed in about one-quarter of stage I adenocarcinomas. In regard to the p53 pathway, the frequency of immunohistochemical positivity was 8% for p14ARF, 64% for MDM2, 20% for p53 and 24% for p21. In this pathway, the immunohistochemical profile of p14ARF-negative/MDM2-positive/p53-negative is characteristic of stage I adenocarcinoma of the lung. An inverse relationship was found between MDM2 and p53 protein and was associated with the differentiation status of stage I adenocarcinoma of the lung. Our results suggest that the disruption of the pRb and p53 pathways is frequently observed in the early stages of lung adenocarcinoma and might play an important role in the growth and differentiation of adenocarcinoma of the lung.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11940214     DOI: 10.1046/j.1440-1827.2002.01321.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  6 in total

1.  p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).

Authors:  Leonie Saft; Mohsen Karimi; Mehran Ghaderi; András Matolcsy; Ghulam J Mufti; Austin Kulasekararaj; Gudrun Göhring; Aristoteles Giagounidis; Dominik Selleslag; Petra Muus; Guillermo Sanz; Moshe Mittelman; David Bowen; Anna Porwit; Tommy Fu; Jay Backstrom; Pierre Fenaux; Kyle J MacBeth; Eva Hellström-Lindberg
Journal:  Haematologica       Date:  2014-03-28       Impact factor: 9.941

2.  Proteomic signatures associated with p53 mutational status in lung adenocarcinoma.

Authors:  Ayumu Taguchi; Oliver Delgado; Müge Celiktaş; Hiroyuki Katayama; Hong Wang; Adi F Gazdar; Samir M Hanash
Journal:  Proteomics       Date:  2014-11-20       Impact factor: 3.984

Review 3.  Roles of ARF tumour suppressor protein in lung cancer: time to hit the nail on the head!

Authors:  Ruju Vashi; Bhoomika M Patel
Journal:  Mol Cell Biochem       Date:  2021-01-03       Impact factor: 3.396

4.  Enhancive effect of N,N'-dinitrosopiperazine on inducing precancerous lesion on nasal and/or nasopharyngeal epithelia of TgN(p53mt-LMP1)/HT mice.

Authors:  Dao-fa Tian; Ying-chun He; Fang-guo Lu; Fa-qing Tang
Journal:  J Zhejiang Univ Sci B       Date:  2009-03       Impact factor: 3.066

5.  Effect of the WWOX gene on the regulation of the cell cycle and apoptosis in human ovarian cancer stem cells.

Authors:  Hongchao Yan; Jianye Tong; Xiaoman Lin; Qiuyu Han; Hongxiang Huang
Journal:  Mol Med Rep       Date:  2015-04-17       Impact factor: 2.952

6.  Clinicopathological significance of p14ARF expression in lung cancer: a meta-analysis.

Authors:  Fang Wang; Heping Li; Jianting Long; Sheng Ye
Journal:  Onco Targets Ther       Date:  2017-05-08       Impact factor: 4.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.